TBScience 2020 Programme

Please find the TBScience 2020 scientific progamme.

TBScience 2020 will be incorporated into the 51st Union World Conference on Lung Health, which is being held virtually for the first time this year. This is the third annual TBScience, an official event entirely devoted to basic and translational tuberculosis (TB) research.

TBScience brings together scientists from microbiology, immunology, molecular biology, pharmacology, epidemiology and mathematical modelling to present and discuss recent findings on TB transmission, infection and disease. Additional focus is also given to the development of better vaccines, new drugs and diagnostics for TB.

  • Wednesday, 21 October

    THEME: Role of innate and adaptive immunity in TB, and evaluation of immune correlates in preclinical and clinical studies

    Session description: In this session recent insights into the host immune response to Mtb infection will be discussed. The results from a first TB biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by four selected abstract presentations and close with an open panel discussion.

    Session moderators: Prof Frank Cobelens, University of Amsterdam, The Netherlands; Prof Tom H. M. Ottenhoff, Leiden University Medical Centre, the Netherlands; Prof David Lewinsohn, Oregon Health & Sciences University, USA

    15:00 – 16:30 CEST

    Role of innate and adaptive immunity in TB, and evaluation of immune correlates in preclinical and clinical studies – Plenary session

    TB Biomarkers, and first results of the CORTIS trial Prof. Thomas Scriba, Department of Pathology, University of Cape Town, South Africa
    BCG vaccination, trained immunity, tuberculosis and COVID-19 Prof. Reinout van Crevel, Radboud University Medical Center, The Netherlands
    Role of antibodies and B cells in TB Prof. Galit Alter, Ragon Institute of MGH, MIT, and University of Harvard, USA

    16:30 – 17:15 CEST

    Role of innate and adaptive immunity in TB, and evaluation of immune correlates in preclinical and clinical studies – Oral abstract presentations

    Inflammatory markers in the cerebrospinal fluid linked to mortality in tuberculous meningitis Ms. Valerie A.C.M. Koeken, Radboud University Medical Center, The Netherlands
    Vaccination with intravenous BCG protects SIV+ macaques from tuberculosis. Dr. Erica Larson, University of Pittsburgh, USA
    A pilot study on plasma metabolomic characterization of patents with MDR-TB Dr. Qi Tan, The First Affiliated Hospital of Nanjing Medical University, China
    A 22-gene transcriptomic model predicting individual therapy durations in multidrug-resistant tuberculosis Dr. Jan Heyckendorf, Research Center Borstel, Germany

    17:15 – 18:00 CEST

    Correlates of risk versus protection – Panel discussion

    Moderated by Prof. Barry Bloom, Harvard University, Cambridge, USA

    Panelists: Prof. Thomas Scriba, University of Cape Town, South Africa; Prof. Reinout van Crevel, Radboud University Medical Center, the Netherlands; Dr. Galit Alter, Ragon Institute of MGH, MIT, and Harvard, Cambridge, USA; Dr. Ann Ginsberg, The Bill and Melinda Gates Foundation, USA

  • Thursday, 22nd October

    THEME: Dead or alive? Implications of spectrum of M. tuberculosis infection

    Session description: Recent research has suggested that M. tuberculosis can present as more subtle states than just “latent” infection and active disease. This has relevant diagnostic, preventive, therapeutic, transmission, modeling and economic analyses implications. This session is intended to discuss different implications of the spectrum of TB infection.

    Session moderators: Dr Richard Anthony, National Institute for Public Health and the Environment (RIVM), the Netherlands; Dr Iñaki Comas, Biomedicine Institute of Valencia, Spain

    15:00 – 16:30 CEST

    TB infection and disease: the details – Plenary session

    Subclinical TB in epidemiological models: What we know, what we don’t and what difference it makes Prof Emily Kendall, Johns Hopkins University in Baltimore, USA
    Bacterial and host determinants of cough aerosol culture-positivity in patients with drug-resistant or drug-susceptible TB Prof. Grant Theron, Stellenbosch University, South Africa
    Natural history of subclinical tuberculosis tracked by PET/CT and blood biomarkers Dr. Anna Coussens, University of Cape Town, South Africa

    16:30 – 17: 15 CEST

    Bacterial metabolic activity and the host response in TB disease – Oral abstract presentations

    Transcriptomic profile of aerosolized Mycobacterium tuberculosis from patients during the early phase of drug-sensitive anti-tuberculosis treatment Dr. Ambreen Shaikh, The Foundation for Medical Research, India
    Antigen-specific T cell activation distinguishes between recent and remote tuberculosis infection Dr. Elisa Nemes, University of Cape Town, South Africa
    Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease Dr. Jon C. Emery, London School of Hygiene and Tropical Medicine, UK
    Cough-independent production of metabolically active Mycobacterium tuberculosis in bioaerosol Dr. Benjamin Patterson, University of Amsterdam, Amsterdam, The Netherlands

    17:15 – 18:00 CEST

    Dead or alive? Implications of spectrum of M. tuberculosis infection – Round table

    Moderated by Dr. Christina Yoon, University of California San Francisco, USA

    Panelists: Dr. Simone Joosten, Leiden University Medical Center, The Netherlands; Dr. Rein Houben, London School of Hygiene and Tropical Medicine, UK; Dr. Paul Drain, University of Washington, USA

  • Friday, 23rd October

    THEME: What is new in drug-resistance detection

    Session description: Multiple active anti-mycobacterial drugs are required to cure tuberculosis. Monotherapy or treatment with insufficient active drugs accelerates the development of mycobacterial resistance resulting in treatment failures and ultimately undermines elimination strategies. For this reason, understanding the detailed mechanisms of resistance as well as interactions between the host and different drugs is important as it allows in vivo activity to be predicted. This session aims to discuss recent findings with respect to our understanding of anti-mycobacterial drug resistance and the prediction of susceptibility notably based on genome sequence data.

    Session moderators: Dr Claudia Denkinger, University Hospital Heidelberg, Germany;  Dr Iñaki Comas, Biomedicine Institute of Valencia, Spain

    15:00 – 16:30 CEST

    What is new in drug-resistance detection – Plenary session

    Sequencing to Support DR TB Treatment Decisions: A New Landscape of Options​ Prof. Timothy Rodwell, University of California, San Diego, USA
    From MoR to MoA to new drugs Prof. Thomas Dick, Hackensack Meridian Medical School at Seton Hall University, USA
    The role of M. tuberculosis within-host heterogeneity. Can it inform TB patient care? Prof. Maha Farhat, Harvard Medical School, USA

    16:30 – 17: 15 CEST

    Latest research in drug resistance detection, mechanism and treatments – Oral abstract presentations

    Association of delamanid concentrations with treatment outcomes or drug resistance among patients with MDR-TB. Dr. Daniel S. Graciaa, Emory University School of Medicine, USA
    High frequency of bedaquiline resistance in programmatically treated drug-resistant TB patients with sustained culture-positivity in Cape Town, South Africa Ms. Brigitta Derendinger, Stellenbosch University, South Africa
    ncRv0842c, a smallRNA regulating the efflux pump Rv0842 involved in rifampicin tolerance in M. tuberculosis Mr. Paolo Miotto, IRCCS San Raffaele Scientific Institute, Italy
    Genomic sequence characteristics and the empirical accuracy of short-read sequencing in Mycobacterium tuberculosis Ms. Maximillian Marin, Harvard Medical School, USA

    17:15 – 18:00 CEST

    The detection of genetic variants associated with antibiotic tolerance, persistence and drug resistance

    Moderated by Dr. Richard Anthony, National Institute for Public Health and the Environment (RIVM), the Netherlands

    Panelists: Prof. Maha Farhat, Harvard Medical School, USA; Dr. Richard Anthony, National Institute for Public Health and the Environment (RIVM), the Netherlands; Prof. Thomas Dick, Hackensack Meridian Medical School at Seton Hall University, USA and Prof. Sarah Fortune, Harvard T.H. Chan School of Public Health, USA; Prof. Timothy Rodwell, University of California, San Diego, USA.

  • Saturday, 24th October

    THEME: Innovations in TB Therapeutics

    Session description: TB therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is much welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions, and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development, and genomic discoveries with relevance to development of host-directed therapies for curing TB.

    Session moderators: Prof Payam Nahid, University of California, USA; Prof Amina Jindani, St. George’s, University of London, UK

    15:00 – 16:30 CEST

    Innovations in TB Therapeutics – Plenary session

    Opportunities and Risks: Using therapeutic TB vaccines to improve cures and shorten treatment for active disease Prof. Gavin Churchyard, London School of Hygiene & Tropical Medicine, UK
    Single-bacilli response to drug exposure within lesional microenvironments: Bug-drug interactions within the granuloma and beyond Dr. Joshua Vasquez, University of California San Francisco, USA
    Diversity of Mycobacterium tuberculosis and clinical outcomes  of tuberculosis. The challenges posed for optimizing HDT for TB Dr. Margarida Saraiva, University of Porto, Portugal
    Q&A Moderated by Prof Payam Nahid, University of California, USA; Prof Amina Jindani, St. George’s, University of London, UK

    16:30 – 17: 15 CEST

    Innovations in TB Therapeutics – Oral abstract presentations

    An empirical modeling approach for regimen development: How to build a winning team. Dr. Natasha Strydom, University of California San Francisco, San Francisco, United States of America
    The role of respiratory microbiome in early bactericidal activity of anti-tuberculosis therapy and treatment outcome Dr. Wilber Sabiiti, University of St Andrews, United Kingdom of Great Britain and Northern Ireland
    In silico assessment of adaptive trial design for TB regimen development Mr. Vincent Chang, University of California San Francisco, San Francisco, United States of America
    Translational platform for predicting clinical outcomes for new combination regimens using pre-clinical and phase I data Dr. Qianwen Wang, University of California San Francisco, San Francisco, United States of America

    17:15 – 18:00 CEST

    Innovations in TB Therapeutics – Panel discussion

    Moderator: Dr. Debra Hanna, The Bill and Melinda Gates Foundation, USA

    Panelists: Prof. Gavin Churchyard, London School of Hygiene & Tropical Medicine, UK; Dr.Joshua Vasquez, University of California San Francisco,  USA; Dr. Margarida Saraiva, University of Porto, Portugal; Prof. Amina Jindani, St. George’s, University of London, UK, Dr. Rada Savic, University of California San Francisco, USA.

Back to top

Receive Conference News & Updates